トップページ

2006/8/28 Mylan Laboratories

Mylan Laboratories to Acquire Up to 71.5% Controlling Interest in Matrix Laboratories
- Transaction Expected to be Accretive to Mylan in FY '08 -

ジェネリック(後発医薬品)メーカー米2位のマイラン・ラボラトリーズは、インドの製薬会社マトリックス・ラボラトリーズの経営権を最大7億3600万ドル(約860億円)で取得する。アジアと欧州市場への参入を狙う。

Mylan Laboratories Inc. and Matrix Laboratories Ltd. today announced that Mylan will acquire up to 71.5% of Matrix shares outstanding for Rs. 306 per Matrix share. Under the terms of the transaction, Mylan will purchase 51.5% of Matrix's shares outstanding pursuant to an agreement with certain selling shareholders and will make an "open offer" to Matrix's remaining shareholders to acquire up to an additional 20% of Matrix's shares outstanding. Assuming the open offer is fully subscribed, the total purchase price is expected to be approximately $736 million. Matrix will remain a publicly traded company in India and will continue to operate on an independent basis.

Strategic Rationale
Mylan and Matrix together will have approximately 5,100 employees in 10 countries. Matrix will provide Mylan with a significant presence in important emerging pharmaceutical markets, including India, China, and Africa, as well as a European footprint and distribution network through Matrix's Docpharma subsidiary. By combining Matrix's
active pharmaceutical ingredient (API) and drug development business with Mylan's expertise in finished dosage forms (FDFs), this transaction also will allow Mylan to capture incremental pieces of the value chain through backward vertical integration. Additionally, Matrix will expand Mylan's capabilities in a number of key areas including products with higher barriers to entry and long-term growth opportunities, and allow the company to pursue a broader portfolio of new products at lower costs. As part of the Mylan organization, Matrix will benefit from a strong U.S. presence, expanded production capabilities and manufacturing capacity, and industry-leading expertise in product development and process optimization.

Matrix is the
world's second largest API player with respect to the number of drug master files (DMFs), with over 165 APIs in the market or under development, and 10 API and pharmaceutical intermediate manufacturing facilities, six of which are FDA approved. Matrix has diverse API capabilities, knowledge of the API patent landscape, capability in early API development, a low cost structure and strong scientific capabilities. Matrix's API manufacturing platform will provide Mylan with significant cost savings and enable first in-last out product lifecycles. Their finished dosage form pipeline will expand Mylan's forms and therapeutic categories and allow Mylan to pursue a broader portfolio of product opportunities more economically.

About Mylan
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, please visit http://www.mylan.com/.

About Matrix
Matrix Laboratories Limited is a public limited company listed on BSE and NSE, and is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms. Matrix is one of the fastest growing API manufacturers in India and focuses on regulated markets such as U.S. and EU. The company has a wide range of products in CNS, anti-bacterial, anti-AIDS, anti-asthmatic, cardiovascular, gastrointestinal, anti-fungal, pain management and life style related therapeutic segments. Six API manufacturing facilities of the Matrix Group are approved by the U.S. FDA. The combined FDA approved capacity of the company is one of the largest in the country. The company's Finished Dosage Forms (FDF) manufacturing facility has a capacity to manufacture 2 billion tablets and 300 million capsules on two-shift basis. With about 2,300 employees, including over 300 R&D scientists, Matrix focuses on developing APIs with non-infringing processes to partner with generic players in regulated markets for their early formulation entry. It has recently acquired Docpharma, Belgium, for a front-end presence in Belgium, the Netherlands and Luxembourg. In addition Matrix has a controlling stake in Mchem (China) and Concord Biotech India. Newbridge Capital/TPG Ventures, U.S., and Temasek Holdings, Singapore, are the strategic investors in Matrix with combined holding of about 40 percent.


PLASTICS NEWS  2006/12/21

Supreme Petrochem boosting EPS capacity

Supreme Petrochem Ltd. of Mumbai is adding 132 million pounds (60,000t ) of expandable polystyrene capacity at its Nagothane, India, styrenics complex.
The project, now under way, will give Supreme its first EPS capacity at Nagothane. The existing complex already can produce nearly 600 million pounds(
272,000t ) of PS annually.

A business development team also is being readied for EPS marketing, said Supreme
s senior general manager, Sharad Parate. The firm is accelerating its expansion into EPS since it took over control of Chennai, India-based Shin Ho Petrochemical (India) Ltd.

We are already doubling the Chennai plant capacity to 26.5 million pounds (12,000t ) by this coming March,Parate said during the Society of Plastics Engineers conference, held Dec. 7-8 in India. He added that Shin Hos name changed to SPL Polymers Ltd. after Supreme took charge in April.

The firm has the ability to double EPS capacity at the Nagothane plant, based on market demand, he noted.

Overall, Supreme would be investing $225 million by 2011 in ongoing and planned expansions, which will include more value-added products, such as ABS.

The expansion also includes increasing PS capacity at Nagothane to 882 million pounds(400,000t) annually by 2009, according to Parate, who pointed out that Supreme
s PS resins are exported to 78 countries.

Supreme Petrochem is a joint venture of Mumbai-based firms Supreme Industries Ltd. and Rajan Raheja Group. Supreme Industries, established in 1950, claims to be Indias largest plastics processor, with 18 plants across the country doing injection molding and film, foam and pipe extrusion. Rajan Raheja is a diversified firm holding interests in a variety of businesses.

  立地   計画  
SPL Nagothane PS 272,000t → 400,000t by 2009
EPS 60,000t   建設中
SPL Polymers
(旧称 Shin Ho Petrochemical
Chennai EPS  6,000t →  12,000t 2007/3

Supreme Petrochem Ltd    http://www.supremepetrochem.com/

Supreme Petrochem Ltd (SPL), owns and operates a state-of-the art Polystyrene facility, with an installed capacity of 272,000 TPA located at Nagothane in Raigad District, about 100 Kms south-east of Mumbai city. The facility also includes a world class colouring and compounding facility with an installed capacity of 17,000 TPA.

The Plant is based on technology from the erstwhile Huntsman Chemical Corporation (Now NOVA Chemicals) USA with basic engineering by ABB Lummus Crest, USA.

 


日本経済新聞夕刊 2007/4/2

経済特区 インド、計画中止続々
 反対農民抗議デモ 政府、政策見直し必至

 インド政府が主導する経済特区(SEZ)建設計画が厳しい逆風にさらされている。土地収用に抗議した農民と警官隊の衝突で野党や労組などの非難が集中。東部オリッサ州、西ベンガル州の大規模SEZが相次ぎ中止に追い込まれた。首都ニューデリー郊外のハリヤナ州でも新たな抗議デモが起き、中央・州政府は政策の大幅な見直しを迫られる見通しだ。
 オリッサ州政府は3月28日、金属産業の誘致を目指した同州中部カリンガナガールのSEZ計画を無期限に凍結すると発表。西ベンガル州政府も同日、南部ナンディグラムで進めていたSEZの移転を決めた。両SEZの建設に反対した抗議デモでは、いずれも農民らに多数の死傷者が出ている。
 外資系企業などが集中するハリヤナ州グルガオン郊外では28日、大手財閥リライアンスのSEZ予定地に多数の農民が集結し、重機に投石した。同州産業インフラ開発公社は「農民らは既に補償を受けている」と困惑している。
 有力経済紙エコノミック・タイムズによると、印政府は印西部ムンバイでSEZを計画中のリライアンスに対し、住民移転問題がこじれそうな土地の取得を中止し開発規模を縮小するよう要請する見通し。


Platts 2007/7/12

India to complete acetic acid, acetyl chloride plants by 2008

India's IOL Chemicals & Pharmaceuticals Ltd. plans to bring online its first monochloro acetic acid and acetyl chloride plants at Barnala, Punjab, by June 2008, a company source said Wednesday.

When on-stream, the plants will have the capacity to produce 6,000 mt/year of monochloro acetic acid and 5,000 mt/year of acetyl chloride.



IOL recently boosted its ibuprofen plant capacity to 3,600 mt/year from 1,800 mt/year, and plans to add another 3,600 mt/year plant by December 2009.

In December 2006, the company debottlenecked its acetic acid plant capacity from 30,000 mt/year to 50,000 mt/year, its ethyl acetate yield from 18,000 mt/year to 33,000 mt/year and acetic anhydride capacity from 7,500 mt/year to 12,000 mt/year.


2007/7/17 Platts

IG Petrochemicals considering PA expansion at Taloja

IG Petrochemicals Ltd is considering expanding its phthalic anhydride production capacity, the company said Monday.

'The Board of Directors of the Company has considered and approved the proposed expansion of capacity,' said IG Petrochemicals in a statement after the board meeting on Monday evening. The company currently operates
120,000 mt/year phthalic anhydride plant at Taloja, near Mumbai.

An IG Petrochemicals official said that the size of the new capacity would be decided after a feasibility study and would be added in the second half of 2008.



IG Petrochemicals had previously increased its production phthalic anhydride from 45,000 mt/year to 120,000 mt/year at Talo


I G Petrochemicals

Incorporated in the year 1988 as 100% Export Oriented Unit (EOU), I G Petrochemicals Limited has relentlessly marched towards achieving its goals and objectives.

Our principal business revolves around the production of Phthalic Anhydride, which is mainly used in the manufacture of Plasticizers for production of PVC products, shoe soles and other commodities, Alkyd Resins for manufacturing of paints, as an intermediate in production of dyes and pigments, and in production of Unsaturated Polyester Resins (UPRs).

The plant is located at MIDC, Taloja in Raigad District, Maharashtra, India, 50 Km away from Jawaharlal Nehru Port Trust (JNPT), Nhavasheva.


Platts 2007/10/17

Indian SAPL-IFC in talks on loan for Egypt's PET resin project

India's South Asian Petrochem Ltd. is in talks with the International Finance Corp. on the sale of an equity stake and a loan for development of a 315,000 mt/year polyethylene terephthalate resin plant at Damietta on Egypt's Mediterranean coast, a company official said Tuesday.
(IFC
がエジプト計画のためにSAPLに融資を行い、同社の株式を購入する)

The Kolkata-based SAPL early this year entered into a joint venture agreement with Egyptian Petrochemical Holding Co. to set up a PET resin plant at Damietta by the end of 2009. SAPL will hold 70% equity in the project, while Echem and Engineering for the Petroleum & Process Industries will own 23% and 7%, respectively.

The project, the first PET plant in North Africa, will export to Europe and North Africa, besides catering to the Egyptian market. SAPL, India's second-largest PET manufacturer, operates a
180,000 mt/year Bottle Grade PET resin plant at Haldia in West Bengal, close to the Mitsubishi's PTA plant.

国際金融公社(IFC)
開発途上国で民間セクターへの投融資を持続可能な形で促進し、貧困削減と人々の生活水準の向上に役立つこと、それがIFCの使命です。

http://www.ifc.org/ifcext/spiwebsite1.nsf/0/6f58a8630c470efb8525736b0074fe64?OpenDocument

South Asian Petrochem Limited (SAPL or the sponsor), India's second largest manufacturer of Polyethylene Terephthalate (PET), is planning to set up a joint venture with the Egyptian Petrochemical Holding Company (Echem), an agency of the Government of Egypt (GoE), to establish a 315,000 tons per annum (tpa) greenfield PET resin plant in Damietta, on Egypt's Mediterranean coast. SAPL will have a 70% share in Egyptian Indian Polyester Co. (EIPET or the project company) whereas Echem will hold 23% and Engineering for the Petroleum & Process Industries (Enppi) will hold the balance 7%. The project has an estimated cost of approximately $135 million (including working capital requirements).

PET, which is produced from mono ethylene glycol (MEG) and terephthalic acid (PTA), is sold in small pellets and its major use is for the manufacture of lightweight plastic bottles for carbonated soft drinks and water. The project's output is expected to be exported to Europe and the United States and also sold in Egypt, Middle East and North Africa.

The project will be the first PET plant in North Africa. Egypt has significant advantages for the location of a PET plant including:
- low logistics costs for sales to the European Union (EU) and North American markets;
- access to the fast growing and underserved African and Middle Eastern markets;
- excellent port/infrastructure facilities;
- favorable trade agreements with the EU; and
- proximity to sources of MEG feedstock.


January 31, 2008 Tata Group

Tata Chemicals acquires 100-per cent stake in General Chemical Industrial Products Inc, USA

Tata Chemicals (TCL), part of the Tata Group, has entered into definitive agreements to acquire the soda ash business of General Chemical Industrial Products Inc (GCIP), a US based chemical company, for US$1,005 million. Harbinger Capital Partners is GCIP's majority shareholder. The transaction is subject to shareholder and regulatory approvals.

GCIP's subsidiary, General Chemical (soda ash) Partners (GCSAP), is a significant soda ash producer in the US with a capacity of 2.5 million tpa of natural soda ash. GCSAP has mining and manufacturing facilities located at Green River Basin in Wyoming, USA, which provides it access to the world's largest and most economically recoverable trona ore deposits that is then converted into soda ash.

The acquisition of GCIP will lead to a sizeable increase in TCL's global soda ash capacity making it one of the largest soda ash producers worldwide. Over 50 per cent of this capacity will be from the natural route, which is a significantly more economical route of producing soda ash than the synthetic route and is a natural hedge against the commodity cycle. This acquisition, together with its other global soda ash facilities, will give TCL a unique market position.

The merger will provide TCL access to markets in North America, Latin America and the Far East, which complement its existing markets.


October 26, 2009

A. Schulman announces plans to establish a masterbatch facility in India

A. Schulman, Inc. announced today it plans to establish a masterbatch facility in western India to better serve its customers in the region, which is a key geographic growth market for A. Schulman. A specific location for the facility has not yet been determined.
The facility initially will consist of one line and will manufacture the Companys masterbatch products which serve the packaging, appliance and consumer products markets. Its capacity is projected to be approximately 12 million pounds per year, and production is expected to begin within the next 12 months.
In line with our strategic direction, we are continuing our geographic expansion in growing markets across Asia,said Joseph M. Gingo, Chairman, President and Chief Executive Officer.
The new plant, which will be our third manufacturing facility in Asia, will increase our capability to serve our growing customer base in this attractive market and will be another step in our progress toward becoming the number-one global manufacturer in the masterbatch market.


2010/4/3 日本経済新聞

丸紅、 インドでタイヤ原料生産 国営企業と合弁

丸紅はインドでタイヤ原料の製造に乗り出す。国営インド石油、台湾の合成ゴム大手台橡(TSRC)と合弁会社を設立、約180億円を投じ工場を建設する。2012年には現在のインドの年間需要量に匹敵する12万トンの原料を生産する計画だ。インドの自動車市場は急成長しており、日本メーカーも相次ぎ生産能力の増強に動いている。丸紅などは今後の需要増を見越した積極投資で、成長市場 を開拓する。

 5月にも3社共同で合弁会社 Indian Synthetic Rubber(ハリヤナ州)を設立する。資本金は未定だが、インド石油が50%、 TSRCが30%、丸紅が20%を出資する。

 インド石油は国内に8カ所の製油所を保有し、石油化学品事業の拡大を進めている。今春からエチレンプラントのナフサクラッカー(分解設備) が稼働。新会社は同クラッカーの副産物として産出するブタジエンを使い、タイヤの主原料となるスチレンブタジエンゴム(SBR)を生産する。

 工場はインド石油のエチレンプラントに隣接する土地に建設し、SBRの生産にはTSRCの技術を導入する。現在、インドではSBRを全量輸 入に依存しているが、国内生産に順次切り替えていく考えだ。

 インドの09年度の自動車生産台数は09年4月〜10年2月までの11カ月間で259万台と、08年度の実績をすでに30万台以上上回って いる。今後も成長を続け、将来は中国や米国に匹敵する市場に拡大するのは確実で、関連する日本メーカーの投資も加速している。

 タイヤメーカーではブリヂストンが約500億円を投じてインドで2工場目となる新工場を建設する。13年に稼働し、20年には現地生産能力 を現状より約8割増やす。

 完成車では日産自動車が仏ルノーとの合弁工場を立ち上げ、5月から戦略小型車「マイクラ(日本名マーチ)」の量産を開始。トヨタ自動車は 11年前後の稼働を目指し、インド第2工場を建設中で排気量1000cc級の小型車を生産する。スズキも12年の稼働を目指し、マネサール工場(ハリヤナ 州)の敷地内に年産25万台の能力を持つ新工場を建設する。

ーーー

2006年5月30日、東洋エンジニアリングはインド向け大型エチレン設備をインドのエンジニアリング会社と 連合で受注したと発表した。

発注元はインド国営石油会社(IOCLで、ハリアナ州パニパットのパニパット製油所(原油処理能力・年間 600万トン)の隣接地にエチレン・コンプレックスを建設するもので、このうち、年産800千トンエチレン製造設備(ナフサ・ベース)を受注したもの。

本設備はインド最大かつ北インド初のエチレン製造設備で、 IOCLが建設する初のエチレンプラントである。

IOCLは2004年6月にハリアナ州政府との間で、エチレンコンプレックス建設の覚書を締結、本 年4月に州政府産業開発公社との間で計画遂行のためのJV設立の覚書を締結した。出資比率等の詳細は未定。

計画ではエチレン857千トン、プロピレン650千トンをベースに、HDPE、PP、MEGを建設する。
IOCLは別途、同地で2006年稼動予定でナフサを原料にPX 360千トンとPTA 553千トンのPTAプラントを建設中だが、JVではこれを原料にPET樹脂を製造することも検討する。

ほかにGujarat Refinery120千トンのLABを持つ。

2006/6/5 インドのエチレン計画 

 


21 June 2011

Aditya Birla Group completes Columbian Chemicals deal

The Aditya Birla Group today announced the completion of the transaction relating to its acquisition of the Atlanta-based Columbian Chemicals Company, subsequent to having obtained all regulatory approvals in seven different jurisdictions. The acquisition of Columbian Chemicals was made at a price of US $ 875 million. It catapults the Aditya Birla Group to the worlds No. 1 carbon black producer.

The newly constituted Board of Directors for Columbian Chemicals is chaired by Mr. Kumar Mangalam Birla, Chairman, Aditya Birla Group. Other Directors from the Group, include Mrs. Rajashree Birla, Mr. Rajiv Dube, Dr. Santrupt Misra, Mr. D. D. Rathi and Mr. Kevin Boyle, CEO, Columbian Chemicals.

Says Mr. Birla, We view the Carbon Black business as a significant global business in our portfolio. There is a lot to be derived from this coming together of the two entities. Columbian Chemicalsexcellent R&D capability, multiple speciality products, customer connect in North America and South America, coupled with committed teams, will add to the strength of the Carbon Black business. Likewise, our strength in scale economies, managing large capacity plants and managing multiple emerging markets, will be leveraged. This, together, with the experience and expertise that our teams have in growing an acquired companys revenues and earnings significantly, should enable us take the Carbon Black business to a far higher plane.” 

Adds Dr. Santrupt Misra, The completion of the acquisition of Columbian Chemicals is indeed a milestone in our Carbon Black business. At one stroke it doubles our capacity, from 1 million tons to 2 million tons. It extends our geographic reach. Our global footprint now spans 12 countries ? India, Thailand, Egypt, China, USA, Brazil, Korea, Spain, Canada, Hungary, Germany and Italy, where we collectively have 17 state-of-the-art manufacturing units. The deal helps in giving us a foothold in the mature markets of North America and strengthens our position in Europe and in emerging markets. Our focus is on unrelenting value creation and optimizing costs through innovation in areas such as logistics, sourcing and technology. We expect synergies in excess US $ 50 million.

The Aditya Birla Group is among the most cost efficient manufacturers of carbon black. It is a global provider of high quality carbon black additives that cater to the requirements of leading tyre and other rubber manufacturers. Its products also service the ink and plastic segments.  

A US $30 billion corporation, the Aditya Birla Group is in the League of Fortune 500. It is anchored by an extraordinary force of over 131,000 employees, belonging to 42 different nationalities. The Group has been adjudged among the top two Best Employers in India by the Aon?Hewitt Study conducted recently. Earlier it has been rated as the six great places for leaders to work in the Asia Pacific Region (The Hewitt Associates, The RBL Group and Fortune Magazine Study 2009). The Group operates in 33 countries. Over 60 per cent of its revenues of US $ 30 billion flow from its overseas operations.

Globally, the Aditya Birla Group is:

:: A metals powerhouse, among the world's most cost-efficient aluminium and copper producers. Hindalco-Novelis is the largest aluminium rolling company. It is one of the three biggest producers of primary aluminium in Asia, with the largest single location copper smelter
:: No.1 in viscose staple fibre
:: The fourth-largest producer of insulators
:: The fourth-largest producer of carbon black
:: The fifth-largest producer of acrylic fibre
:: The eighth-largest cement producer
:: Among the best energy-efficient fertiliser plants

In India:

:: One of the leading cement producers
:: The top fashion (branded apparel) and lifestyle player
:: The second-largest producer of viscose filament yarn
:: The second-largest in the chlor-alkali sector
:: Among the top four mobile telephony companies
:: Among top 10 Indian BPO companies by revenue size
:: A leading player in life insurance and asset management
:: Among the top three supermarket chains in the retail business

Columbia Chemical

We are a global provider of high-quality carbon black additives for rubber, plastic, and liquid products. Our products add strength, durability, and enhanced performance to products consumers use every day such as automobile tires and toner in printers.

Our company has been in business for more than 100 years, and this is attributable in part to our commitment to providing value to our customers. We believe that each customer is unique, with a different set of needs based on individual markets, strategies and competitive dynamics. At Columbian Chemicals Company, we are committed to understanding your needs so that we can better help you succeed. We offer a wide range of carbon black products for rubber, plastic, liquid, and other industrial applications that are designed to get you the results you need.

 

Columbians history dates back to the 1860s when carbon black was first utilized for industrial applications.  The companys name today evolved from Columbian Carbon Company, which was formed in 1922 from the consolidation of several small carbon black manufacturers.  Throughout its rich history, Columbian has led the way in many areas of the carbon black industry.  Here is a sampling of the many firststhat Columbian Chemicals brought to the industry: 

In 1986 Columbian was acquired by Phelps Dodge Corporation and over the next two decades the company expanded its operations in Europe and acquired operations in South America and Asia. 

Phelps Dodge Corporation was an American mining company founded in 1834 by Anson Greene Phelps and William Earle Dodge, Sr.. On March 19, 2007, it was acquired by Freeport-McMoRan and now operates under the name Freeport-McMoRan Copper & Gold Inc.

In March of 2006, Columbian was acquired by a company jointly owned by DC Chemical Co. and One Equity Partners. DC Chemical is a leading South Korean company, based in Seoul. One Equity Partners is a private equity affiliate of J.P. Morgan Chase & Co. 

In November 2009, One Equity Partners bought out the controlling interest in Columbian.

January 6, 2009

DC Chemical Sells Stake In Columbian Chemicals
South Korean chemical maker sells its holdings in carbon black maker to reduce debt

Citing deteriorating global financial conditions, South Korea's
DC Chemical says it has signed a definitive agreement to sell its 67% stake in carbon black maker Columbian Chemicals. Private equity firm One Equity Partners, which now owns 33% of Columbian Chemicals, will pay $150 million for DC Chemical's stake in a deal expected to close by the end of March.

In 2006, DC Chemical and One Equity bought Columbian from
Phelps Dodge International for $600 million, including debt. DC Chemical says it decided to sell its stake to focus on fast-growing core businesses, including polysilicon for solar cells. DC Chemical also says the sale will help it mitigate global risks and reduce debt in a difficult financial environment.

韓国ではKCCのほか、OCI(旧東洋製鉄化学 DC Chemical )が16,500トン、Woongjin5,000トンのポリシリコン工場を持っており、サムスンとLGが進出を計画している。

Not counting the debt it undertook to acquire the Columbian stake, DC says it invested $257 million in the carbon black maker. And even though the cash it will receive from One Equity-an affiliate of JPMorgan Chase-is less than its original investment, the firm calls the transaction "timely and prudent" given current economic conditions.

Based in Marietta, Ga., Columbian operates 12 facilities in the Americas, Europe, and Asia, employing 1,300 people. The carbon black it makes is used to enhance the strength and durability of rubber tires and as a pigment in plastics and printing inks.

OCI Corporation("OCIC") is a well-established trading company based in Seoul, Korea. OCIC's business includes export, import, and local distribution of chemicals and chemical-related products with energetic professionals who have knowledge, experience and dedication.l

2001 Launched as DC Chemical
2005 Acquired Sodiff Advanced Materials (OCI Materials)
2006 Acquired Columbia Chemicals
2008 Established Shandong DC Chemical
   Launched polysilicon production
2009 Completed No.2 polysilicon plant and started No.3 polysilicon plant
   Renamed as OCI
2010 Completed Shandong DC Chemical (SDC) coal tar plant

OCI
(
DC Chemical )

Kunsan

 TDI 50

Kwangyang

 Benzen 170
Toluen
 30

 


2012/7/17 equities.com                           BPCL to offer 51% to LG Chem in proposed Kochi petrochem unit

India : BPCL, LG CHEM ink MoU to setup petrochemical plant in Kerala

Bharat Petroleum Corporation Ltd. (BPCL) has inked a MoU with LG Chem (South Korea) for creating a Joint Venture to set up a petrochemical plant next to its Kochi Refinery complex.

India s second-largest public sector Oil Marketing Company, BPCL would be spending around Rs 14,000 Crores during the next five years for expansion of its Kochi Refinery.

BPCL would be installing a Petrochemical Fluid Catalytic Cracker (PFCC) which would produce 500 TMTPA of Propylene, thus, offering BPCL a launching pad for diversification into Petrochemicals.

The petrochemical project, which is scheduled for completion in the next four years dovetailed with the refinery expansion project, would be set up in the JV mode at an extra cost or Rs 4.000-6.000 Crores next to the Kochi Refinery.

-------

Bharat Petroleum Corporation Limited (BPCL) is an Indian state-controlled oil and gas company headquartered in Mumbai, India.

In 1860s during vast industrial development, an important player in the South Asian market was the Burmah Oil Company. Though incorporated in Scotland in 1886, the company grew out of the enterprises of the Rangoon Oil Company, which had been formed in 1871 to refine crude oil produced from primitive hand dug wells in Upper Burma.

In 1928, Asiatic Petroleum Company (India) started cooperation with Burma oil company. This alliance led to the formation of Burmah-Shell Oil Storage and Distributing Company of India Limited. Burmah Shell began its operations with import and marketing of Kerosene.

On 24 January 1976, the Burmah Shell was taken over by the Government of India to form Bharat Refineries Limited. On 1 August 1977, it was renamed Bharat Petroleum Corporation Limited. It was also the first refinery to process newly found indigenous crude Bombay High.

Operations
Bharat Petroleum owns refineries at Mumbai, Maharashtra and Kochi, Kerala (Kochi Refineries) with a capacity of 12 and 9.5 million metric tonnes per year.

------------

Sep 24, 2012   business-standard.com/india/ 

BPCL to offer 51% to LG Chem in proposed Kochi petrochem unit

State-run oil marketer Bharat Petroleum Corporation (BPCL), which is setting up its first propylene unit in Kochi, said it was ready to offer 51 per cent stake in the Rs 6,000-crore project to its Korean joint venture partner LG Chemicals.

‘We have already inked an MoU (memorandum of understanding) with LG Chemicals for this project. They are looking at 51 per cent stake in the JV (joint venture) and we are open to that. The JV company will be in place by December or January and the plant will be commissioned by the end of financial year 2017,” BPCL Finance Director S Varadarajan said.

He said the propylene plant is part of the company’s proposed petrochemicals complex planned at Ambalamugal near Kochi, where it also has a 9.5 million tonne oil refinery.

On September 14, BPCL Chairman and Managing Director R K Singh had inked an MoU with Kerala Chief Minister Oommen Chandy at the Emerging Kerala investor summit in Kochi that attracted Rs 2.5 trillion (Rs 2.5 lakh crore) worth proposals, for Rs 20,000-crore investment in the state. Varadarajan said this is the single largest investment by the company so far and involves expansion of the Kochi Refinery capacity to 15.5 million tonne per annum from the present 9.5 million tonne by FY17. The remaining Rs 6,000 crore will go into the greenfield petrochemicals complex.

When asked about the details of tax benefits that Kerala has offered, Varadarajan said, “BPCL will be cumulatively getting Rs 7,500 crore in tax deferments over 15 years since commissioning of the both plants. This works out to be around Rs 500 crore annually.

“But from the 16th year onwards, we will have to start paying back this to the state. So, this practically is loan from the state.” When asked about land acquisition, Varadarajan said BPCL already has almost enough land at the Ambalamugal complex.

“We may probably need just about 70 more acres which the government has with it. Any day the government will transfer that to us,” he said.

He further said both the projects are scheduled to be completed by the end of FY17. Over the weekend, the BPCL Chairman had told reporters after its AGM last Friday that BPCL has lined up a capital expenditure of up to Rs 45,000 crore by 2017 and the Kochi projects are part of this. “In the next four to five years our total capex will be to the tune of around Rs 40,000-45,000 crore. This allocation will be spent on upstream, refinery expansion and other infrastructure development,” Singh had said.

On the fund raising plan for this capex, Singh said raising funds to this magnitude would not be a problem as BPCL is already in talks with the domestic banks.

“We have no problem in mobilising this kind of resources because we have some good discoveries. Many banks are willing to fund our activities,” he said.

For funds for its many exploration projects, Varadarajan said a consortium of domestic banks led by State Bank, is ready to lend. But he added that these will be dollar- dominated borrowings. The company has many gas blocks in Mozambique, 10 oil blocks in Brazil, and some oil and gas blocks in Indonesia, Australia, Britain, East Timor, and a shale gas project. To a question on Cove Energy's stake in resource-rich prospective gas block in Mozambique, which it plans to offload, Singh said BPCL is interested in purchasing Cove's holdings but for high valuation.


August 14, 2013 Business Standard

Birla plans to invest $1 bn in US chemical plant  

The shale gas boom in the US has attracted one more Indian company, Aditya Birla Group, which is reportedly planning to invest $1 billion for setting up a chemical/fertilizer plant. Already, Indian companies such as Reliance Industries,  Gail India, etc have either acquired announced mega investment in shale assets in the US.

The Aditya Birla Group move is also aided by the fact that the US economy has started to show remarkable growth in the last few months. The company has not yet clarified whether the investment will be in a greenfield projects or through acquisition.


The Aditya Birla group is planning to invest $1 billion in setting up a chemical/fertiliser plant in the US to take advantage of the falling gas prices in that country.

Another reason for the big-ticket investment plan was a reviving business sentiment there, a top official said.

"We have been looking at an investment in the US, as there is enough and cheap gas - priced at $3-3.50 a unit. So, like a lot of Indian chemical companies, we are looking at the country for investment in the next few months," said Aditya Birla Nuvo Managing Director Rakesh Jain. He added, depending on its due-diligence report, the group would make the investment either in a greenfield (new) plant or through an acquisition. A team was already camping in the US to scout for opportunities.

The Aditya Birla Group is an Indian conglomerate; a dominant player in viscose staple fibre, metals, cement, branded apparel, financial services & other sectors.

Around the world, we're known for:

A metals powerhouse, among the world’s most cost-efficient aluminium and copper producers.
Hindalco-Novelis is the largest aluminium rolling company.
It is one of the three biggest producers of primary aluminium in Asia with the largest single location copper smelter

No.1 in viscose staple fibre
No.1 in carbon black
The fourth-largest producer of insulators
The fifth-largest producer of acrylic fibre
Among the top 10 cement producers
Among the best energy-efficient fertiliser plants
The largest Indian MNC with manufacturing operations in the USA

In India, here’s what we have accomplished:

The largest fashion (premium branded apparel) and lifestyle player
The second-largest manufacturer and largest exporter of viscose filament yarn
The largest producer in the chlor-alkali sector
Among the top three mobile telephony companies
A leading player in life insurance and asset management
Among the top two supermarket chains in the retail business
Among the top 6 BPO companies
The largest manufacturer of linen fabric

Aditya Birla Chemicals is a leading manufacturer of bulk and speciality chemicals and viscose filament yarn. The business is spread across multiple manufacturing locations in three countries – India, Thailand and China.

Aditya Birla Chemicals is creating a footprint in the chemicals industry: in the chlor-alkali segment, it is a market leader in India; in viscose filament yarn, it stands at number two position and in sulphites, it is the third largest manufacturer in the world.

Our presence
In India, the business operates through four companies: Aditya Birla Nuvo, Grasim Industries, Aditya Birla Chemicals (India) and Tanfac.

In Thailand, the business operates through two companies: Aditya Birla Chemicals (Thailand) and Thai Peroxide Company.

In China, the Chemicals business operates through Aditya Birla Grasun Chemicals (Fangchenggang).

Product segments
The Chemicals business manufactures a wide range of products using advanced technology and ensuring stringent quality control. Our product portfolio includes:
 Chlor-alkali
 Sulphites
 Chlorine derivatives
 Peroxides
 Epoxy resins
 Fluorine chemicals
 Phosphates and phosphoric acid
 Viscose filament yarn

July 23, 2015 

インド後発薬大手ルピン、米国の同業ガビスを買収

Lupin Acquires GAVIS to Expand US Generic Business

Pharma Major Lupin Limited (Lupin) has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., subject to certain closing conditions, in a transaction valued at USD 880 million, cash free and debt free. The transaction has been unanimously approved by the Boards of Directors of Lupin and GAVIS. The acquisition enhances Lupin’s scale in the US generic market and also broadens Lupin’s pipeline in dermatology, controlled substance products and other high-value and niche generics. GAVIS brings to Lupin a highly skilled US based R & D organization which would complement Lupin’s Coral Springs, Florida, inhalation R&D center. GAVIS’s New Jersey based manufacturing facility will become Lupin’s first manufacturing site in the US.

New Jersey based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products. GAVIS recorded sales of $96 million in FY 2014 and has over 250 New Jersey based employees. GAVIS currently has 66 ANDA filings pending approval with the US FDA and a pipeline of over 65+ represent niche dosage forms. To date, GAVIS has filed 25 Para IVs and 8 FTFs products. GAVIS’s pending filings address a market value of about USD 9 billion. The combined company will have a portfolio of 101 in-market products, 164 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest portfolio of ANDA filings with the US FDA, addressing a USD 63.8 billion market. products under development. 72% of these filings pending approvals

Commenting on the acquisition, Ms. Vinita Gupta, Chief Executive Officer of Lupin Limited said, "This is a pivotal acquisition for Lupin as it aligns with our goal to expand and deepen our US presence. GAVIS has a strong track record of delivering highly differentiated products in a short time and is poised for continued strong growth as it delivers on its existing pipeline. GAVIS’s capabilities and pipeline are an excellent complement to Lupin. The acquisition accelerates Lupin’s entry into niche areas like controlled substances and dermatology. We are confident that Lupin’s proven commercialization capabilities, vertically integrated manufacturing operations and supply chain strengths will accelerate GAVIS’s growth. The acquisition is expected to be accretive to the earnings from the first full year of operations. In addition to the compelling strategic fit, there is a strong cultural fit between GAVIS and Lupin’s entrepreneurial spirit and values.”

Novel Laboratories is an independent research, development, and manufacturing company, which has commercialized over 20 pharmaceutical products since our inception in 2007. Novel boasts significant operations in the U.S. with a state-of-the-art 40,000-square-foot research, development and manufacturing facility with an additional 100,000 square feet of space scheduled to come online in 2015. Among the 250 employees at Novel at our New Jersey facility, you’ll find seasoned executives and managers, dedicated and bright scientific staff, skilled and efficient business development and legal personnel and conscientious manufacturing and packaging staff, along with the knit in sales and distribution staff at our affiliate GAVIS Pharmaceuticals LLC.

In December of 2006 Novel Laboratories is formed by Dr. Veerappan Subramanian and a small team of industry veterans as a full-service research, development, and manufacturing company with the goal of developing generic pharmaceutical products with high technical barriers to entry.

In 2008 GAVIS Pharmaceuticals is formed as a generic pharmaceutical sales, marketing, and distribution company, complementing Novel's development and manufacturing operations.

共和薬品工業は2007年10月、拡大するジェネリック医薬品市場において、研究開発力、製造力を高めるため、グローバルスタンダードに基づきジェネリック医薬品を世界市場に展開しているインドのジェネリック医薬品メーカー・ルピン社と資本提携致しました。

インド系企業による日本のGEメーカーの買収は、ザイダスグループによる日本ユニバーサル薬品の買収に続き2社目だった。